INMB Stock Forecast: INmune Bio, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.83
−7.49% on the day

The median 12-month analyst price target for INmune Bio, Inc. is $8. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 38 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$27.7M
Ticker Nerd rank
38/ 100
Median analyst target
$8.00
Analysts covering
3
Revenue$0.0
Operating income−$1.5M
Net income−$1.3M
Free cash flow−$3.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−21.2%
1M
−48.3%
YTD
−47.0%
1Y
−44.5%
From 52W high
−67.1%
From 52W low
0.0%
$0.83
$2.51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores INmune Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
38/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
87
Accruals
51
Momentum
45
Value
39
Volatility
38
Quality
30
Issuance
28
Revisions
25

Growth (87): Sales and profits are climbing, and climbing faster than before.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

INMB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INMB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26INMBHigh $9.00Median $8.00Low $2.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$2.50
Low
$8.00
Median
$9.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Nov 2026Freedom BrokerMaintainsBuy$4.00 → $2.50
11 Mar 2026LUCID CAPITAL MARKETSUpgradeBuy$2.00 → $9.00
2 July 2025Maxim GroupMaintainsBuy—
1 July 2025BTIGDowngradeNeutral—
1 July 2025ScotiabankDowngradeSector Underperform—
13 Feb 2025Maxim GroupMaintainsBuy—
11 Feb 2025ScotiabankMaintainsSector Outperform—
21 Oct 2024Alliance Global PartnersInitiatesBuy$20
27 Sept 2024Raymond JamesInitiatesOutperform$18
22 Aug 2024ScotiabankInitiatesSector Outperform$22
1 June 2023BairdInitiatesOutperform—
24 May 2022B. Riley SecuritiesDowngradeNeutral—
24 May 2022BTIGMaintainsBuy—
24 Jan 2022B. Riley SecuritiesMaintainsBuy—
21 Apr 2021B. Riley FBRInitiatesBuy—
21 Apr 2021B. Riley SecuritiesInitiatesBuy—
25 Nov 2020BTIGInitiatesBuy—
25 Nov 2020H.C. WainwrightReiteratesBuy—
25 Nov 2020HC Wainwright & Co.MaintainsBuy—
25 Nov 2020Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for INMB.

Market Radar

This page is one stock. Monday covers all of them.

INMB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

INMB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, INmune Bio, Inc. returned −44.5% against +6.9% for the S&P 500, dividends included.

INMB vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160180Jan 26Apr 26Jul 26Oct 26INMBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INMB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
553.6×

Cheaper than 1% of US stocks

Price / book
1.4×

Cheaper than 58% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−76.7%

Higher than 16% of US stocks

Return on assets
−40.5%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • INmune Bio, Inc. has a market value of $27.7M and an enterprise value of $12.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$18.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$15.7M.

  • Shares outstanding: 27.7M.

  • INmune Bio, Inc. employs 21 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

INMB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INMBINmune Bio, Inc.$27.7M38
LONALeonaBio, Inc.$26.4M25
EYPTEyePoint, Inc.$26.6M21
TELOTelomir Pharmaceuticals, Inc.$26.8M27
KLRSKalaris Therapeutics, Inc.$26.8M27
PTHSPelthos Therapeutics, Inc.$24.4M37
LITSLite Strategy, Inc.$24.4M33

Take a look at INMB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own INmune Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about INMB

What is the INMB stock price forecast for 2026-2027?

The median 12-month analyst price target for INmune Bio, Inc. is $8, with estimates ranging from $2.5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INMB stock a buy right now?

Of the 3 analysts covering INmune Bio, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks INmune Bio, Inc. 38 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INMB?

As at 21 Nov 2026, INmune Bio, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).

Will INMB stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $8, and Ticker Nerd's factor model ranks INmune Bio, Inc. 38 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INMB stock forecast for 2030?

No analyst covering INmune Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INMB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $9 over the next 12 months.

How has INMB stock performed over the past year?

INmune Bio, Inc. returned -44.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does INmune Bio, Inc. do?

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that modulate the innate immune system to address cancer, neuroinflammation, and other immune-mediated diseases. Its current product platforms include INKmune, a cell-based therapy designed to prime natural killer cells for oncology applications; INB03 and XPro1595, which target tumor necrosis factor-driven inflammation; and CORDstrom, a mesenchymal stem cell-based platform.

Company

About INmune Bio, Inc.

INmune Bio Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that modulate the innate immune system to address cancer, neuroinflammation, and other immune-mediated diseases. Its current product platforms include INKmune, a cell-based therapy designed to prime natural killer cells for oncology applications; INB03 and XPro1595, which target tumor necrosis factor-driven inflammation; and CORDstrom, a mesenchymal stem cell-based platform. The company’s programs are aimed at hematologic malignancies, solid tumors, chronic inflammation, and neurological conditions such as Alzheimer’s disease and treatment-resistant depression. INmune Bio Inc. works through a precision medicine approach, matching mechanisms of action to patient biology and clinical outcome measures. Headquartered in Boca Raton, Florida, the company operates in the biotechnology and immunology markets and focuses on advancing therapies that harness the body’s own immune response to fight disease.

CEO Mr. David J. Moss M.B.A. · 21 employees · United States · https://www.inmunebio.com